Pediatric Liver Transplant With Campath 1H Induction - Preliminary Report

T. Kato, G. Selvaggi, T. Panagiotis, E. Hernandez, G. McLaughlin, J. Moon, S. Nishida, D. Levi, John F. Thompson, N. Halliday, P. Ruiz, A. Tzakis

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Since Campath 1H (C1H) has been successfully used in adult liver transplant recipients since 2001 in our program, we started to use it in children. Patients and Methods: C1H induction was employed in 10 children with autoimmune hepatitis (AIH) (n = 6), primary sclerosing cholangitis (PSC) (n = 1), biliary atresia (n = 1), glycogen storage disease (n = 1), and Wilson's disease. Eight were primary transplants, and two retransplants. Patients ages ranged from 5 to 17 years. C1H was administered at a dose of 0.3 mg/kg on days 0, 4, and 7. Tacrolimus level was maintained at 5 to 10 ng/mL. No patient received maintenance steroids posttransplantation except two who were on steroid therapy at the time transplant. They were prescribed small doses of maintenance steroids. Median follow-up of C1H recipients was 679 days (range 115-1143). Results: Postoperative courses were mostly uneventful except for one retransplant recipient who required prolonged hospitalization (40 days) for rehabilitation. Median hospital stay was 12 days (range 7-40 days). All 10 patients in the C1H group are currently alive and well with stable graft function. No opportunistic infection was observed in these patients to date. We compared six patients with AIH who received C1H to the historic control of 10 recipients with AIH who received conventional immunosuppression (tacrolimus + steroid). The patients treated with C1H showed significantly prolonged rejection-free survival. Conclusion: In our preliminary experience, C1H induction was well tolerated in pediatric liver recipients. Rejections-free survival was prolonged among recipients with AIH despite a low level of maintenance immunosuppression.

Original languageEnglish (US)
Pages (from-to)3609-3611
Number of pages3
JournalTransplantation Proceedings
Volume38
Issue number10
DOIs
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

Pediatrics
Transplants
Autoimmune Hepatitis
Liver
Steroids
Maintenance
Tacrolimus
Immunosuppression
Glycogen Storage Disease Type I
Biliary Atresia
Sclerosing Cholangitis
Hepatolenticular Degeneration
Survival
alemtuzumab
Opportunistic Infections
Length of Stay
Hospitalization
Rehabilitation

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Kato, T., Selvaggi, G., Panagiotis, T., Hernandez, E., McLaughlin, G., Moon, J., ... Tzakis, A. (2006). Pediatric Liver Transplant With Campath 1H Induction - Preliminary Report. Transplantation Proceedings, 38(10), 3609-3611. https://doi.org/10.1016/j.transproceed.2006.10.039

Pediatric Liver Transplant With Campath 1H Induction - Preliminary Report. / Kato, T.; Selvaggi, G.; Panagiotis, T.; Hernandez, E.; McLaughlin, G.; Moon, J.; Nishida, S.; Levi, D.; Thompson, John F.; Halliday, N.; Ruiz, P.; Tzakis, A.

In: Transplantation Proceedings, Vol. 38, No. 10, 12.2006, p. 3609-3611.

Research output: Contribution to journalArticle

Kato, T, Selvaggi, G, Panagiotis, T, Hernandez, E, McLaughlin, G, Moon, J, Nishida, S, Levi, D, Thompson, JF, Halliday, N, Ruiz, P & Tzakis, A 2006, 'Pediatric Liver Transplant With Campath 1H Induction - Preliminary Report', Transplantation Proceedings, vol. 38, no. 10, pp. 3609-3611. https://doi.org/10.1016/j.transproceed.2006.10.039
Kato T, Selvaggi G, Panagiotis T, Hernandez E, McLaughlin G, Moon J et al. Pediatric Liver Transplant With Campath 1H Induction - Preliminary Report. Transplantation Proceedings. 2006 Dec;38(10):3609-3611. https://doi.org/10.1016/j.transproceed.2006.10.039
Kato, T. ; Selvaggi, G. ; Panagiotis, T. ; Hernandez, E. ; McLaughlin, G. ; Moon, J. ; Nishida, S. ; Levi, D. ; Thompson, John F. ; Halliday, N. ; Ruiz, P. ; Tzakis, A. / Pediatric Liver Transplant With Campath 1H Induction - Preliminary Report. In: Transplantation Proceedings. 2006 ; Vol. 38, No. 10. pp. 3609-3611.
@article{b3140cb1301b42aeb99a30079318307d,
title = "Pediatric Liver Transplant With Campath 1H Induction - Preliminary Report",
abstract = "Since Campath 1H (C1H) has been successfully used in adult liver transplant recipients since 2001 in our program, we started to use it in children. Patients and Methods: C1H induction was employed in 10 children with autoimmune hepatitis (AIH) (n = 6), primary sclerosing cholangitis (PSC) (n = 1), biliary atresia (n = 1), glycogen storage disease (n = 1), and Wilson's disease. Eight were primary transplants, and two retransplants. Patients ages ranged from 5 to 17 years. C1H was administered at a dose of 0.3 mg/kg on days 0, 4, and 7. Tacrolimus level was maintained at 5 to 10 ng/mL. No patient received maintenance steroids posttransplantation except two who were on steroid therapy at the time transplant. They were prescribed small doses of maintenance steroids. Median follow-up of C1H recipients was 679 days (range 115-1143). Results: Postoperative courses were mostly uneventful except for one retransplant recipient who required prolonged hospitalization (40 days) for rehabilitation. Median hospital stay was 12 days (range 7-40 days). All 10 patients in the C1H group are currently alive and well with stable graft function. No opportunistic infection was observed in these patients to date. We compared six patients with AIH who received C1H to the historic control of 10 recipients with AIH who received conventional immunosuppression (tacrolimus + steroid). The patients treated with C1H showed significantly prolonged rejection-free survival. Conclusion: In our preliminary experience, C1H induction was well tolerated in pediatric liver recipients. Rejections-free survival was prolonged among recipients with AIH despite a low level of maintenance immunosuppression.",
author = "T. Kato and G. Selvaggi and T. Panagiotis and E. Hernandez and G. McLaughlin and J. Moon and S. Nishida and D. Levi and Thompson, {John F.} and N. Halliday and P. Ruiz and A. Tzakis",
year = "2006",
month = "12",
doi = "10.1016/j.transproceed.2006.10.039",
language = "English (US)",
volume = "38",
pages = "3609--3611",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Pediatric Liver Transplant With Campath 1H Induction - Preliminary Report

AU - Kato, T.

AU - Selvaggi, G.

AU - Panagiotis, T.

AU - Hernandez, E.

AU - McLaughlin, G.

AU - Moon, J.

AU - Nishida, S.

AU - Levi, D.

AU - Thompson, John F.

AU - Halliday, N.

AU - Ruiz, P.

AU - Tzakis, A.

PY - 2006/12

Y1 - 2006/12

N2 - Since Campath 1H (C1H) has been successfully used in adult liver transplant recipients since 2001 in our program, we started to use it in children. Patients and Methods: C1H induction was employed in 10 children with autoimmune hepatitis (AIH) (n = 6), primary sclerosing cholangitis (PSC) (n = 1), biliary atresia (n = 1), glycogen storage disease (n = 1), and Wilson's disease. Eight were primary transplants, and two retransplants. Patients ages ranged from 5 to 17 years. C1H was administered at a dose of 0.3 mg/kg on days 0, 4, and 7. Tacrolimus level was maintained at 5 to 10 ng/mL. No patient received maintenance steroids posttransplantation except two who were on steroid therapy at the time transplant. They were prescribed small doses of maintenance steroids. Median follow-up of C1H recipients was 679 days (range 115-1143). Results: Postoperative courses were mostly uneventful except for one retransplant recipient who required prolonged hospitalization (40 days) for rehabilitation. Median hospital stay was 12 days (range 7-40 days). All 10 patients in the C1H group are currently alive and well with stable graft function. No opportunistic infection was observed in these patients to date. We compared six patients with AIH who received C1H to the historic control of 10 recipients with AIH who received conventional immunosuppression (tacrolimus + steroid). The patients treated with C1H showed significantly prolonged rejection-free survival. Conclusion: In our preliminary experience, C1H induction was well tolerated in pediatric liver recipients. Rejections-free survival was prolonged among recipients with AIH despite a low level of maintenance immunosuppression.

AB - Since Campath 1H (C1H) has been successfully used in adult liver transplant recipients since 2001 in our program, we started to use it in children. Patients and Methods: C1H induction was employed in 10 children with autoimmune hepatitis (AIH) (n = 6), primary sclerosing cholangitis (PSC) (n = 1), biliary atresia (n = 1), glycogen storage disease (n = 1), and Wilson's disease. Eight were primary transplants, and two retransplants. Patients ages ranged from 5 to 17 years. C1H was administered at a dose of 0.3 mg/kg on days 0, 4, and 7. Tacrolimus level was maintained at 5 to 10 ng/mL. No patient received maintenance steroids posttransplantation except two who were on steroid therapy at the time transplant. They were prescribed small doses of maintenance steroids. Median follow-up of C1H recipients was 679 days (range 115-1143). Results: Postoperative courses were mostly uneventful except for one retransplant recipient who required prolonged hospitalization (40 days) for rehabilitation. Median hospital stay was 12 days (range 7-40 days). All 10 patients in the C1H group are currently alive and well with stable graft function. No opportunistic infection was observed in these patients to date. We compared six patients with AIH who received C1H to the historic control of 10 recipients with AIH who received conventional immunosuppression (tacrolimus + steroid). The patients treated with C1H showed significantly prolonged rejection-free survival. Conclusion: In our preliminary experience, C1H induction was well tolerated in pediatric liver recipients. Rejections-free survival was prolonged among recipients with AIH despite a low level of maintenance immunosuppression.

UR - http://www.scopus.com/inward/record.url?scp=33845524641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845524641&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2006.10.039

DO - 10.1016/j.transproceed.2006.10.039

M3 - Article

VL - 38

SP - 3609

EP - 3611

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -